CUTLL1 In Vitro Aortic Ring Assay (Angiogenesis) (CAT#: ITS-1122-YF5622)

CUTLL1

Human

The CUTLL1 cell line was established from pleural effusion of a relapsed 14-year-old male patient suffering from T-cell lymphoblastic lymphoma.

Acute Lymphoblastic Leukemia; ALL

Oncology

In Vitro Aortic Ring Assay (Angiogenesis)

CUTLL1-cell based In Vitro Aortic Ring Assay (Angiogenesis)

Aortic rings from mouse thoracic aorta or chicken embryos are normally used in these assays. Prepared aortic rings are placed in Matrigel matrix in cell culture well plates with testing angiogenic factors or inhibitors. Microvessels sprouting from aortic rings can be monitored over a period of 6-12 days using an inverted microscope. Irregularities in the aortic segments have been identified as one of the drawbacks of this assay.

Angiogenesis Monitoring Assays

Local and regional metastasis is a life-threatening condition in cancer, which is hard to control with the available cancer treatment options. In metastasis, cancer cells move away from primary tumors and travel through the blood and lymphatic system and form new tumors on other parts. A vascular
network growth is important for cancer metastasis. Angiogenesis is a process that is known as the formation of new blood vessels with the help of existing blood vessels and angiogenesis has been reported to play a major role in cancer growth and metastasis. Tumors can send chemical signals to nearby normal tissues to stimulate angiogenesis. New blood vessels can feed growing tumors with nutrients and oxygen, allowing cancer cells to spread (metastasis).